Background Prevalence of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in the injecting drug user (IDU) community can differ considerably. In Australia in 1997, HIV prevalence among attendees at Needle Exchange Programs was 1% while HCV prevalence was 50%. The impact that different needle-sharing behaviour and drug injecting use may have on the future levels of these viruses is uncertain.
In a number of countries, injecting of illicit drugs has been recognized as an important pathway for the transmission of blood-borne viruses. Of particular concern have been epidemics of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among drug users, arising through the sharing of equipment used in injecting. In many parts of the world, the prevalence of HIV infection among people who inject drugs has risen to 40-60% in the space of a few years. Hepatitis C virus prevalence has generally been found to be at least 50% in this population. As the parenteral route is the dominant mode of transmission of HCV, 1 and a major source of HIV infection, 2 the avoidance of sharing injecting equipment can have a large impact on reducing the spread of HIV and HCV.
There has been considerable debate about the value of needle and syringe distribution programmes, and the impact of other approaches to reducing the risk of blood-borne virus transmission among injecting drug users (IDU). Epidemiological studies of the effect of prevention activities are very difficult to carry out in this population, because of the challenges of follow-up and confounding. Mathematical modelling provides an alternative means of obtaining insight into the dynamics of viral transmission among IDU, including the consequences of specific interventions in this population. A number of authors have used this approach over the past decade. [3] [4] [5] [6] [7] [8] [9] [10] Kaplan, 3 uses a model with two differential equations describing prevalence and the probability of infection for HIV, where sharing occurs only in shooting galleries. Greenhalgh & Hay, 4 extend Kaplan's model to allow some different behaviour in the rate of visitation of shooting galleries and the likelihood of infection. Peterson et al. 5 use a Monte Carlo approach. Massad et al. 6 develop a dynamical model that tracks HIV-infected needles and their interaction with infected and uninfected IDU. Iannelli et al. 7 use a contact model that does not explicitly parameterize sharing. Kretzschmar & Wiessing 8 require the specification of an underlying social network. The most extensive model is by Blower et al. 9 This dynamical model investigates HIV infection through heterosexual and IDU contact for IDU in New York city. It allows contact through buddy and stranger user groups and is gender specific. The disadvantage of this model is the 30 parameters that require specification. A model of HCV transmission among IDU is found in ref. 10 .
In order to gain an understanding of the potential impact of changes in the level of drug injecting and the reuse of equipment on the spread of HIV and HCV, we develop a new mathematical model of the number of people who inject drugs with each of these infections. The benefits of this new approach to previous ones is that it is applicable to both HIV and HCV, its formulation and implementation are simpler, and it uses data from both diseases to infer values of sharing and injection use. We use the model to predict changes in prevalence of these diseases in the IDU community. Moreover, the model enables a calculation of how far each disease is from effective containment through the calculation of a critical sharing level.
Materials and Methods

The mathematical model
A mathematical model is constructed using differential equations. By definition the term IDU refers to only current IDU. For an infection of interest (HIV or HCV in this case), the model describes I(t), the number of current IDU who have the infection at time t. This number changes over time, according to the rate at which new infections occur in this population, and the rate at which those with infection leave the population, either through death, or by stopping the practice of injecting drugs.
New infections can either occur through the reuse or sharing of equipment, or through other routes such as sexual transmission. Sharing refers to all equipment related to drug use. There is some evidence that equipment such as swabs, tourniquets, and even table-tops can be important in HCV transmission. However their effect is considerably smaller than transmission through shared needles. 11 Sharing also refers to re-use of needles, as these are the dominant transmission vehicle, over extended periods of time. Access to clean needles from Needle Exchange Programs in Australia implies that the majority of sharing will occur in a single injecting episode.
The number of new infections at time t occurring through sharing is assumed to be proportional to the number of current infected IDU in the population. The process can be described graphically as in Figure 1 , where aI is the average rate of new infections per year from needle sharing, bI is the average rate per year of loss of infected IDU through all means, and c is the rate of new infections per year from non-needle sharing means. The differential equation for this process has the form (Eqn 1) A key measure of the impact of transmission is the prevalence of viral infection among IDU. If the total population of IDU, with and without infection, is represented by the function U, then the prevalence at any point in time is given by α(t) = I(t)/U(t).
The parameter a defines the number of new infections per time period that will be transmitted from each currently infected IDU via sharing. It can be represented as
where p is the probability of infection through a single reuse of contaminated equipment by a previously uninfected person, n is the average number of IDU using the same equipment at a given episode of injecting, m is the average number of injecting This result can be understood by noting that when prevalence is low, only one of the n users will generally be infected and, on average this person will fall in the middle of the sequence of reusing. Consequently only the (n -1)/2 users that follow the infected person are at risk of infection.
Critical levels of drug injecting
Containing or reducing total infection numbers depends primarily on the relative sizes of a and b in (Eqn 1). If a is always less than b then infected levels will be maintained solely by input from non-needle sharing c. We define the critical sharing level s c to be the amount at which new infections through sharing can start to increase infection levels beyond that arising from other sources. This occurs when the maximum value of a equals b. As a is a decreasing function of prevalence, the maximal value of a occurs at low prevalence and is given, according to (Eqn 4), by
For each IDU, the number of people that person has shared needles with over the course of a year is given by m(n -1). The critical sharing level for incidence, s ci ≡ m ci (n ci -1), is determined when Table 1 gives estimates and bounds for the parameters required by the model.
The AIDS epidemic led to significant changes in needle sharing and cleaning. Introduction of Needle Exchange Programs in Australia in the latter half of the 1980s, 12 and their systematic expansion in subsequent years, was the basis for several parameters changing over time. Rates of emigration among this population were assumed to be negligible. It was assumed that from 1973, total IDU numbers increased at an annual rate of 7%, reaching 275 000 in 1997, and increased at 5% annually from then on. 13 s m n b r p d Availability of highly active antiretroviral therapy (HAART) in Australia in 1995 has led to lower viral levels in individuals with HIV infection. Accordingly the HIV transmission probability p HIV will have decreased with time. The pre-1995 value of p HIV = 0.02, combined with the expected proportion of individuals with HIV RNA copies per ml in three viral groups, Ͻ400, 400-10 000, and Ͼ10 000 (determined from those proportions of individuals in 1999 receiving no treatment 14 ) , and assuming each log 10 drop in viral levels reduced probability of infection by 2.45, 15 provided probabilities of HIV transmission in each of these groups. The expected probability of HIV transmission in recent times was then determined from the proportion of individuals in 1999 under all treatment types, including no therapy, in each of these three viral groups, and their individual probabilities. This calculation led to p HIV reducing to 72% of its initial level by 1999. This may be an overestimate of the reduction as the calculations were performed on values from individuals registered on the Australian HIV Observational Database that may underestimate untreated individuals.
Sensitivity analysis
Sensitivity to parameter values was determined by the Monte Carlo method using 1000 simulations. Each parameter was assigned a Beta distribution with the parameter value from Table 1 taken as the most likely estimate and the bounds providing 6 SD, so at least 90% CI. Prevalence and incidence values were calculated at 5-yearly intervals for each simulation.
Results
Simulation of human immunodeficiency virus prevalence among injecting drug users in Australia
The model of prevalence dynamics among IDU, and the parameter choices in Table 1 , produce the prevalence levels shown in the top left plot in Figure 2 , along with the range of values for the Monte Carlo simulations. Incidence rates are plotted against literature estimates in the bottom left plot of Figure 2 . The incidence rates model literature estimates closely. In 1997 prevalence was estimated at 0.9% for attendees at Needle Exchange Programs. 14 Our simulations provide an estimate of 0.2% prevalence over all IDU. 
Simulation of hepatitis C virus prevalence among injecting drug users in Australia
Evidence for the HCV epidemic among IDU in Australia points to its outbreak in the late 1950s. Beginning our simulation in 1960 produces the prevalence and incidence levels shown in the two right hand plots in Figure 2 . The HCV prevalence levels for people attending needle and syringe exchange programmes were 63% in 1995, 51% in 1996, and 50% in 1997. 14 Our simulated values provide a reasonable approximation to these figures especially since the data is more likely to represent regular IDU rather than all IDU as here. The simulations also duplicate the decreasing trend for prevalence with increasing incidence.
Critical human immunodeficiency virus sharing
With current values for sharing and cleaning, an assumed 5% annual increase in the number of IDU, and estimated reduction in HIV transmission probability and death due to HAART, we obtain s cp = 31, so that on average every IDU would need to share with 31 others over a year before HIV prevalence would be in danger of rising to significant levels. Current sharing estimates are s = m(n -1) = 6. We would need a fivefold increase in sharing before this critical level was breached and prevalence started to rise to significant levels in the entire IDU community. The critical sharing level for total infected numbers is 17. Without HAART, the critical sharing level for infected numbers would be higher at 22, due mainly to the faster removal through HIV mortality.
Critical hepatitis C virus prevalence
The critical sharing level for HCV prevalence is 5.7, suggesting that HCV prevalence will stay elevated. Although prevalence is seen to fall in the simulation, it will stay above 25% in the long term. Critical sharing level for infected numbers is below 3 and so a more significant decrease in current sharing is required for absolute numbers of HCV-infected IDU to fall.
Harm reduction
The model equations ([Eqn 1], [Eqn 2], [Eqn 3])
, can be modified to incorporate the effects of harm reduction strategies. If a proportion γ of infected IDU know they are infected and use injection equipment last, then the expression for u in (Eqn 3)
If this harm reduction strategy is effected from 2000, then for γ = 0.2 and γ = 0.5 there will be little reduction in HIV prevalence as its main source is from non-sharing sources, and a reduction in HIV incidence in 2005 from 9 to 8 and 6 respectively. However, these strategies may achieve an estimated reduction in HCV prevalence from 32.7% with no harm reduction to 31.3% and 28.7% respectively in 2005. Hepatitis C virus incidence may be reduced from 13 400 in 2005 to 11 600 and 8300 respectively.
Discussion
There has been continuing debate in Australia regarding the effectiveness of needle and syringe exchange programmes, along with other preventive programmes aimed at reducing transmission of infectious diseases among IDU, in the face of the qualitatively very different HIV and HCV epidemics in IDU. These programmes appear to have been very effective at limiting the spread of HIV among IDU in Australia, but ineffective at avoiding or markedly reducing the very large HCV epidemic in IDU. Our model confirms one suggestion made elsewhere 11 that these qualitatively very different epidemics can be explained in terms of the greater HCV infectivity, expressed here through the higher transmission probability p HCV and the less-effective cleaning of HCV-contaminated equipment.
The advantages of modelling HIV and HCV simultaneously is that it provides tighter estimation of the parameters and hence is likely to be more precise in the source of their differences. The majority of the rise in HIV prevalence in IDU is due to infection from non-needle sharing means. The sudden drop in incidence after the peak reflects the impact of the needle exchange programmes and resulting lower sharing of needles.
Needle exchange programmes also affected HCV prevalence and incidence but to a lesser extent. It caused a drop in prevalence but could only stabilize incidence. Hepatitis C virus is more infectious than HIV through needle sharing and so we would expect a lower impact on HCV profiles with reduced sharing and more cleaning.
Clearly there are limitations inherent in the model we have developed. One major limitation is that it assumes a homogeneous group. Although HIV and HCV viral levels differ substantially during the course of infection, no variability in transmission dynamics was included. Due to the limited data available however, our approach here has been to develop a relatively simple model of overall injecting behaviour. Subject to these limitations, the model provides a means of estimating the development of infection levels when injecting behaviour changes. In particular, it provides an estimation of the critical sharing level, that level that divides cases of minimal prevalence from possibly high levels. Defining the sharing level to be the number of people an IDU shares with over a year, we find that the critical sharing level for HIV prevalence is 31, whereas the current estimated sharing level is 6, providing a reasonable buffer before HIV prevalence increases. This explains the low prevalence of HIV in the Australian IDU community. We must recognize that these calculations treat the IDU community as a homogeneous group. Although sharing levels are below the critical level for this group, there will be subgroups, in particular regular IDU concentrated in single geographical areas, which will be closer to or may exceed their own critical sharing level. Assuming the number of annual injecting episodes is 200, a level more indicative of regular IDU, leads to simulated HIV prevalence in 1997 of 1.3%, consistent with the 0.9% observed HIV prevalence in that year among attendees at Needle Exchange Programs. 16 If the number of annual injecting episodes rises to 310 so that m(n -1) equals the critical sharing level for prevalence, then HIV prevalence reaches 4% in 2005.
Highly active antiretroviral therapy has impacted on the dynamics of HIV infection in the general and IDU communities. We have estimated that it has lowered HIV transmission probability per single contact with an HIV-contaminated needle to approximately 70% of the pre-HAART risk, due to lower average HIV RNA levels in peripheral blood. On the other hand, HAART has increased the number of HIV IDU through reduced mortality. These competing effects have led to higher risk as the 80% reduction in HIV progression outweighs the benefits of reduced transmission probability. The effect can be seen in critical HIV sharing level for incidence being reduced from 22, assuming no HAART, to its estimated value of 17 with HAART. For HCV the critical sharing level for prevalence is 5.7, less than current estimates of sharing. The critical sharing level for the number of HCV-infected IDU is below 3, suggesting that sharing will need to halve if HCV incidence is to decrease substantially. The lower needle sharing has caused a drop in prevalence levels over recent years. However, as the current sharing level exceeds the critical sharing levels for both prevalence and number, the percentage and number of HCV-infected IDU will remain significant. The interquartile ranges of HCV prevalence and incidence show substantial infection, a marked contrast to the HIV scenarios (Figure 2 ). This provides further indication that HCV will remain a significant health problem among IDU in Australia, even with lower risk behaviour.
Harm reduction strategies can reduce transmission through needle sharing. Since HIV prevalence is low and supported mainly by new infections from non-sharing sources there will be little impact on HIV prevalence and incidence. For HCV there can be a marked reduction. If 20% (50%) of HCV-infected IDU know they are infected and share equipment last, with this behaviour beginning in year 2000, then in 2005 HCV prevalence will reduce from 32.7% with no harm reduction to 31.3% (28.7%). The HCV incidence will reduce from 13 400 to 11 600 (8300). However, this may be an overestimate of effectiveness as HCV can be transmitted from other contaminated equipment in the immediate environment. 11 Although this model has been applied to the Australian IDU community, it is equally applicable to other communities. The model provides a means of estimating future, and current, infection levels. It estimates critical sharing levels, presenting a well-defined goal for health authorities to achieve significant reduction in infection levels.
KEY MESSAGES
• A mathematical model was developed to study human immunodeficiency virus (HIV) and hepatitis C virus (HCV) dynamics in the injecting drug user community in Australia.
• Simulations indicate that under current behaviour HIV prevalence will remain low in this group but that HCV prevalence will stay elevated.
• Our calculations suggest that a halving of sharing is needed for HCV prevalence to fall significantly.
